Fast Five Quiz: How Much Do You Know About Melanomas?

William James, MD


February 18, 2020

Because the definitive treatment of cutaneous melanoma is surgery, medical management is reserved for therapy of patients with advanced melanoma. Less than one half of patients with deep primaries (> 4 mm) or regional lymph-node involvement have long-term disease-free survival; consequently, these patients are classified as high risk and should be considered for medical therapy. Long-term survival statistics for targeted therapies are in the process of being collected. Significant improvements in even widely metastatic conditions are being reported following appropriate surveillance imaging for early relapse detection.

Targeted medications are generally preferred to older US Food and Drug Administration (FDA)-approved interventions, IFN alfa, IL-2, and combination chemotherapy regimens. Targeted therapies and immunotherapies approved by the FDA for use in melanoma include:

  • Vemurafenib

  • Cobimetinib and vemurafenib (combination)

  • Trametinib

  • Dabrafenib

  • Dabrafenib and trametinib (combination)

  • Encorafenib and binimetinib (combination)

  • Vemurafenib and cobimetinib (combination)

  • Pembrolizumab

  • Nivolumab

  • Nivolumab/ipilimumab (combination)

For more on the treatment of melanoma, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: